

as at April 29, 2022

| TICKER | MUTUAL FUND FUNDSERV CODE(S): | NAV | NAV CHANGE |
|--------|-------------------------------|------------------|-----------------|
| LIFE | | \$22.39 (LIFE) | -2.02% (LIFE) |
| LIFE.B | EVF171 | \$24.03 (LIFE.B) | -1.58% (LIFE.B) |
| LIFE.U | EVF170 | \$21.83 (LIFE.U) | -1.92% (LIFE.U) |
| | | \$20.23 (EVF171) | -2.03% (EVF171) |
| | | \$20.89 (EVF170) | -2.02% (EVF170) |

| MARKET PRICE | STYLE | NUMBER OF HOLDINGS | AUM | TARGET YIELD* |
|---------------------------------|---|--------------------|-------------|---------------|
| (as at May. 2, 2022 at 3:52 pm) | Index-Based with active covered call strategy | 20 | \$228.166 M | 7.00% |
| \$22.31 (LIFE) | | | | |
| \$24.47 (LIFE.B) | | | | |
| \$23.07 (LIFE.U) | | | | |

Investment Objective

LIFE seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, while mitigating downside risk. LIFE invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the Manager. The level of covered call option writing may vary based on market volatility and other factors.



Who Should Consider this Fund?

INVESTORS WHO ARE:

- Seeking capital appreciation through having exposure to global healthcare
- Willing to take the risk associated with equity investments
- Seeking increased yield from covered call strategy

Performance

| TICKER | NAV | 1D | 1M | 3M | 6M | YTD | 1Y | 2Y | 3Y | 4Y | SI** |
|--------|---------|--------|--------|-------|--------|--------|--------|--------|--------|--------|--------|
| LIFE | \$22.40 | -2.02% | -2.30% | 3.58% | -0.51% | -2.75% | 11.68% | 10.41% | 13.46% | 12.06% | 9.27% |
| LIFE.B | \$24.03 | -1.58% | -1.14% | 2.32% | 0.51% | -3.56% | 12.69% | 6.42% | 11.80% | 11.51% | 10.44% |
| LIFE.U | \$21.83 | -1.92% | -3.83% | 1.77% | -3.18% | -5.04% | 7.70% | 10.63% | -- | -- | 11.09% |

** Performance since inception of LIFE and LIFE.B on October 24, 2017; LIFE.U on November 27, 2019.

as at April 29, 2022

Calendar Year Performance

| TICKER/FUND | 2017 | 2018 | 2019 | 2020 | 2021 |
|-------------|--------|--------|--------|-------|--------|
| LIFE | -1.57% | 2.07% | 20.38% | 7.52% | 19.44% |
| LIFE.B | -3.21% | 15.84% | 14.56% | 8.80% | 17.22% |
| LIFE.U | - | - | 1.05% | 9.20% | 16.85% |

Historical Prices (\$) - LIFE

As at April 29, 2022



Cumulative Total Return (%) - LIFE

As at April 29, 2022





Evolve Global Healthcare Enhanced Yield Fund

as at April 29, 2022

Fund Details

| | | |
|--|--|---|
| CUSIP 30051T101 (LIFE) 30051T200 (LIFE.B) 30051T309 (LIFE.U) | TICKER LIFE LIFE.B LIFE.U | LISTING EXCHANGE Toronto Stock Exchange (TSX) |
| ASSET CLASS Global Healthcare | INCEPTION DATE October 24, 2017 (LIFE) July 7, 2020 (EVF171) October 24, 2017 (LIFE.B) July 7, 2020 (EVF170) November 27, 2019 (LIFE.U) | CURRENCY CAD (LIFE) Hedged to CAD (EVF171) CAD (LIFE.B) Hedged to CAD (EVF170) USD (LIFE.U) |
| STYLE Index-Based with active covered call strategy | DISTRIBUTION FREQUENCY Monthly | MANAGEMENT FEE 0.45% (plus applicable sales taxes) (LIFE, LIFE.B, LIFE.U) 0.40% (plus applicable sales taxes) (EVF171, EVF170) |
| REGISTERED ACCOUNT ELIGIBILITY Yes | INDEX Solactive Global Healthcare 20 Index Canadian Dollar Hedged (LIFE, LIFE.B, EVF171, EVF170) Solactive Global Healthcare 20 Index (LIFE.U) | INDEX PROVIDER Solactive AG |
| INDEX TICKER SOLHEALH (LIFE) SOLHEALH (LIFE.B) SOLHEALH (LIFE.U) | WEIGHTING Equal Weighted | REBALANCING SCHEDULE Quarterly |
| FUNDSERV CODE EVF171 EVF170 | INDEX REBALANCING FREQUENCY Quarterly | CLASS A TRAILER 1.00% (plus applicable sales taxes) |

as at April 29, 2022

Top 10 Holdings

As at Apr 29, 2022

| NAME | WEIGHT | TICKER | SECTOR | COUNTRY |
|-------------------------|--------|-----------------|------------------------|---------------|
| Merck & Co Inc | 5.54% | MRK US EQUITY | Consumer, Non-cyclical | UNITED STATES |
| Novo Nordisk A/S | 5.39% | NVO US EQUITY | Consumer, Non-cyclical | DENMARK |
| GlaxoSmithKline PLC | 5.30% | GSK US EQUITY | Consumer, Non-cyclical | BRITAIN |
| Bristol-Myers Squibb Co | 5.30% | BMY US EQUITY | Consumer, Non-cyclical | UNITED STATES |
| CSL Ltd | 5.27% | CSLLY US EQUITY | Consumer, Non-cyclical | AUSTRALIA |
| Johnson & Johnson | 5.21% | JNJ US EQUITY | Consumer, Non-cyclical | UNITED STATES |
| Eli Lilly & Co | 5.12% | LLY US EQUITY | Consumer, Non-cyclical | UNITED STATES |
| Novartis AG | 5.05% | NVS US EQUITY | Consumer, Non-cyclical | SWITZERLAND |
| AstraZeneca PLC | 5.05% | AZN US EQUITY | Consumer, Non-cyclical | BRITAIN |
| Pfizer Inc | 5.02% | PFE US EQUITY | Consumer, Non-cyclical | UNITED STATES |

as at April 29, 2022


Geographic Allocation

As at Apr 29, 2022



Sector Allocation

As at Apr 29, 2022



| NAME | WEIGHT |
|---------------|--------|
| UNITED STATES | 59.21% |
| BRITAIN | 10.35% |
| SWITZERLAND | 9.89% |
| DENMARK | 5.39% |
| AUSTRALIA | 5.27% |
| FRANCE | 4.99% |
| IRELAND | 4.91% |

| NAME | WEIGHT |
|------------------------|---------|
| Consumer, Non-cyclical | 100.01% |

* Estimate only. Actual yield changes daily based on market conditions. Target yield is gross of MER, as at March 31, 2022.

The indicated rates of return are the historical annual compound total returns net of fees (except for figures of one year or less, which are simple total returns) including changes in per unit value and reinvestment of all dividends or distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder that would have reduced returns. The rates of return shown in the table are not intended to reflect future values of the ETF and mutual fund or returns on investment in the ETF and mutual fund. ETFs and mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

Commissions, trailing commissions, management fees and expenses all may be associated with exchange traded funds (ETFs) and mutual funds. Please read the prospectus before investing. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to the ETF and mutual fund. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units. Investors should monitor their holdings, as frequently as daily, to ensure that they remain consistent with their investment strategies.

Investors should monitor their holdings, as frequently as daily, to ensure that they remain consistent with their investment strategies.